CD19-ARM (JANX011)
We are leveraging our expertise in T cell biology and protein engineering to develop a novel class of ARM bispecifics designed to address clinically validated drug targets. In February of 2026, Janux announced it dosed its first patient in a Phase 1 clinical trial in healthy volunteers.
CD19 is an important target for b-cell mediated diseases. We designed JANX011 to drive prolonged drug free remissions as a fully off-the-shelf re-dosable therapeutic for autoimmune diseases.
In preclinical studies, JANX011 demonstrated deep and durable B-cell depletion, in both peripheral blood and tissues, with prolonged memory B-cell reset and no evidence of cytokine release syndrome.
